BRIEF-Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Reuters
Yesterday
BRIEF-Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Dec 24 (Reuters) - Repare Therapeutics Inc RPTX.O:
REPARE THERAPEUTICS ANNOUNCES ACQUISITION OF POLΘ ATPASE INHIBITOR, RP-3467, BY GILEAD SCIENCES FOR UP TO $30 MILLION IN TOTAL CONSIDERATION
REPARE THERAPEUTICS INC - GILEAD TO BUY RP-3467 FROM REPARE FOR UP TO $30 MILLION
REPARE THERAPEUTICS INC - TO RECEIVE $25 MILLION UPFRONT, $5 MILLION ON TECH TRANSFER
Source text: ID:nBw2zwPCla
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.